No abstract

Long non-coding RNAs (lncRNAs) are important regulators and biomarkers of tumorigenesis and tumor metastasis. Long intergenic non-protein-coding RNA 467 (LINC00467) is associated with various cancers. However, the role and mechanism of LINC00467 in colorectal cancer (CRC) promotion are poorly understood. This study aimed to present new details of LINC00467 in the progression of CRC. Reverse transcription–polymerase chain reaction demonstrated that the expression level of LINC00467 in CRC tissues and cell lines was significantly upregulated, which was closely related to the clinical features of CRC. Cell and animal studies showed that the downregulation of LINC00467 expression in CRC cells significantly inhibited cell proliferation, metastasis, and angiogenesis. Moreover, the overexpression of LINC00467 accelerated CRC promotion. Bioinformatics analysis and luciferase reporter assay confirmed that LINC00467 binds to miR-128-3p. Rescue experiments manifested that decreased miR-128-3p level reversed CRC cell inhibition by silencing LINC00467. Furthermore, vascular endothelial growth factor C (VEGFC) was identified as a target of miR-128-3p that could reverse the inhibition of cell growth that is mediated by miR-128-3p. Altogether, our results showed that LINC00467 contributes to CRC progression and angiogenesis via the miR-128-3p/VEGFC axis. Our findings expand the understanding of the mechanisms underlying CRC and suggest potential targets for clinical strategies against CRC.

Recent studies have shown that Lipoyltransferase 1 (LIPT1) is a cuproptosis-key gene that plays a critical role in cancer progression, and therefore exploring the underlying mechanisms and biological functions of LIPT1 may provide potential therapeutic guidance for cancer treatment. Our study explored the expression levels and prognostic values of LIPT1 in pan-cancer by using The Cancer Genome Atlas (TCGA), GEPIA2, and ciBioPortal databases bioinformatics platforms. We found that LIPT1 was aberrantly expressed in most cancer types. patients with kidney Chromophobe (KICH) and kidney renal papillary cell carcinoma(KIRP) with high LIPT1 expression were significantly associated with poor prognosis. However, patients with bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), Lung squamous cell carcinoma (LUSC), Rectum adenocarcinoma (READ), Skin Cutaneous Melanoma (SKCM) with high LIPT1 expression showed good prognosis. In addition, we evaluated the genetic alterations, methylation levels, and immunoassays of pan-cancerous LIPT1. To elucidate the underlying molecular mechanisms of LIPT1, we performed single-cell sequencing to elucidate the expression of LIPT1 associated with DNAdamage, Differentiation, and DNArepair. Thus, these comprehensive pan-cancer analyses suggest that LIPT1 may have potential significance for the progression of various cancers. In conclusion, LIPT1 may be a prognostic and immune-related biomarker for a variety of cancers.